7 Results for "

High-grade gliomas

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "High-grade gliomas" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-10293
CAS No.: 791828-58-5
Purity:  99.44%
Synonyms: INCB007839; INCB7839
Target:  

MMP

Research Areas:  

Cancer

Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al .
loading...
    loading...
Cat. No.: HY-45661
CAS No.: 2370913-42-9
Synonyms: NUV-422
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of CDK2, CDK4 and CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6 inhibitor-resistant HR + HER2 - metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-P99157
CAS No.: 1895083-75-6
Synonyms: Mab 8H9
Target:  

CD276/B7-H3

Research Areas:  

Neurological Disease Cancer

Omburtamab (Mab 8H9) is a mouse monoclonal immunoglobulin G1 (IgG1) antibody targeting B7-H3. Omburtamab specifically binds to the glycoprotein antigen B7-H3, which is widely expressed on the surface of tumor cells. As a targeting carrier for recombinant toxins, it delivers PE38 to inhibit cellular protein synthesis and induce cytotoxicity in antigen-expressing cancer cells. Omburtamab can be used in research related to glioma, breast cancer, osteosarcoma and neuroblastoma .
loading...
    loading...
Cat. No.: HY-157828
CAS No.: 2376765-57-8
Research Areas:  

Neurological Disease Cancer

DSP-0390 is an orally active inhibitor of emopamil binding protein (EBP). DSP-0390 induces cell death by blocking cholesterol biosynthesis in tumor cells. DSP-0390 exhibits antitumor activity in an orthotopic xenograft model of human glioblastoma. DSP-0390 can be used for the research of recurrent high-grade gliomas .
loading...
    loading...
Cat. No.: HY-N19738
CAS No.: 21105-15-7
Obtusaquinone is a blood-brain barrier-permeable Keap1 inhibitor with anticancer activity. Obtusaquinone covalently binds to cysteine residues of Keap1, promotes its ubiquitination and proteasomal degradation, and activates the Nrf2 pathway. Obtusaquinone induces endoplasmic reticulum stress and DNA damage through abnormal accumulation of ROS, and triggers apoptosis of cancer cells. Obtusaquinone prolongs survival in orthotopic xenograft models of pediatric high-grade glioma, and exhibits antitumor activity in glioblastoma and breast cancer models. Obtusaquinone can be used in studies related to glioma and breast cancer .
loading...
    loading...
Cat. No.: HY-10293R
CAS No.: 791828-58-5
Synonyms: INCB007839 (Standard); INCB7839 (Standard)
Target:  

Reference Standards MMP

Research Areas:  

Cancer

Aderbasib (Standard) is the analytical standard of Aderbasib (HY-10293). This product is intended for research and analytical applications. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+ breast cancer, gliomas, et al .
loading...
    loading...
Cat. No.: HY-P992341

Target:  

MMP

Research Areas:  

Cancer

D8P1C1 is a high-affinity ADAM17 inhibitor (with a Kd of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. 89Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .
loading...
    loading...